598 related articles for article (PubMed ID: 34006898)
41. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
Learn PA; Yeh IT; McNutt M; Chisholm GB; Pollock BH; Rousseau DL; Sharkey FE; Cruz AB; Kahlenberg MS
Cancer; 2005 Jun; 103(11):2252-60. PubMed ID: 15834928
[TBL] [Abstract][Full Text] [Related]
42. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
[TBL] [Abstract][Full Text] [Related]
43. Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population.
Hammond JB; Scott DW; Kosiorek HE; Parnall TH; Gray RJ; Ernst BJ; Northfelt DW; McCullough AE; Ocal IT; Pockaj BA; Cronin PA
Clin Breast Cancer; 2022 Feb; 22(2):186-190. PubMed ID: 34462208
[TBL] [Abstract][Full Text] [Related]
44. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
45. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
Charehbili A; van de Ven S; Smit VT; Meershoek-Klein Kranenbarg E; Hamdy NA; Putter H; Heijns JB; van Warmerdam LJ; Kessels L; Dercksen M; Pepels MJ; Maartense E; van Laarhoven HW; Vriens B; Wasser MN; van Leeuwen-Stok AE; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR;
Ann Oncol; 2014 May; 25(5):998-1004. PubMed ID: 24585721
[TBL] [Abstract][Full Text] [Related]
46. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
48. Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.
Sella T; Gelber SI; Poorvu PD; Kim HJ; Dominici L; Guzman-Arocho YD; Collins L; Ruddy KJ; Tamimi RM; Peppercorn JM; Schapira L; Borges VF; Come SE; Warner E; Snow C; Jakubowski DM; Russell CA; Winer EP; Rosenberg SM; Partridge AH
Breast Cancer Res Treat; 2021 Feb; 186(1):157-165. PubMed ID: 33150547
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
51. Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
Palmieri C; Macpherson IR; Yan K; Ades F; Riddle P; Ahmed R; Owadally W; Stanley B; Shah D; Gojis O; Januszewski A; Lewanski C; Asher R; Lythgoe D; de Azambuja E; Beresford M; Howell SJ
Oncotarget; 2016 Mar; 7(11):13209-20. PubMed ID: 26334099
[TBL] [Abstract][Full Text] [Related]
52. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
53. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
[TBL] [Abstract][Full Text] [Related]
54. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
55. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
56. Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.
Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Imai A; Okamoto A; Hamaoka A; Soushi M; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Goto M; Yamada K; Taguchi T
Breast Cancer; 2017 Jan; 24(1):92-97. PubMed ID: 26874836
[TBL] [Abstract][Full Text] [Related]
57. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
[TBL] [Abstract][Full Text] [Related]
58. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
59. Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer.
Chen X; Ye G; Zhang C; Li X; Chen Y; Xie X; Zheng H; Cao Y; Wu K; Ni D; Tang J; Wei Z; Shen K
Breast Cancer Res Treat; 2013 Dec; 142(3):549-58. PubMed ID: 24292815
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
